Cellectar Biosciences Inc (NASDAQ:CLRB) price on Friday, April 19, fall -0.33% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.03.
A look at the stock’s price movement, the close in the last trading session was $3.04. Turning to its 52-week performance, $4.45 and $1.33 were the 52-week high and 52-week low respectively. Overall, CLRB moved -18.77% over the past month.
Cellectar Biosciences Inc’s market cap currently stands at around $97.75 million. Analysts project the company’s earnings per share (EPS) to be -$1, which has seen fiscal year 2022 EPS growth forecast to increase to -$3.91 and about -$2.83 for fiscal year 2023. Per the data, EPS growth is expected to be 9.10% for 2024 and 27.60% for the next financial year.
Analysts have a consensus estimate of -$ for the company’s revenue for the quarter, with a low and high estimate of -$ and -$ respectively.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 3 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that CLRB is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
CLRB’s current price about -17.84% and -17.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.14, while 7-day volatility ratio is 6.00% and 6.55% in the 30-day chart. Further, Cellectar Biosciences Inc (CLRB) has a beta value of 0.99, and an average true range (ATR) of 0.23.
If we refocus on Cellectar Biosciences Inc (NASDAQ:CLRB), historical trading data shows that trading volumes averaged 1.15 million over the past 3 months. The company’s latest data on shares outstanding shows there are 32.26 million shares.
The 9.42% of Cellectar Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 30.37% of the company’s shares. Current price change has pushed the stock 9.39% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CLRB stock continues to rise going into the next quarter.
